Identification of salvianolic acid A as an ADP receptor-selective and Gq/IP₃ pathway-mediated anti-platelet component in Qishen Yiqi.

ABSTRACT:

Background

Antiplatelet therapy is crucial for preventing and treating cardio-cerebrovascular diseases. However, adverse events related to thrombosis or bleeding have been reported in instances of treatment with glycoprotein IIb/IIIa antagonists. It is anticipated that developing new selective platelet inhibitors with high anti-thrombotic efficiency and minimal hemorrhagic side effects is feasible. Qishen Yiqi Dripping Pill (QSYQ), an approved drug for ischemic heart disease, was studied for its anti-thrombotic effects.

Methods and results

Employing a microplate-based platelet aggregation assay, we systematically evaluated QSYQ and its medicinal components, chemical fractions, and compounds from the active fractions, identifying Salvianolic acid A (SAA) as one of the major a

SUBMITTER: Dang W 

PROVIDER: S-EPMC12498442 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature